• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Clonnirit
    / Rafa

    Active Ingredient
    Clonidine HCl 25 mcg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 25 mcg

    full basket chart 504 3183

    Related information


    Adults: Initially 2 tablets twice daily. If after two weeks there has been no remission, increase to 3 tablets twice daily.
    The duration of treatment depends upon the severity of the condition.
    If symptoms continue to occur the patient should be informed that it may take 2-4 weeks until Clonnirit is fully effective.
    Elderly: No specific information on the use of this product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group have been reported.
    Paediatric Population: There is insufficient evidence for the application of clonidine in children and adolescents younger than 18 years. Therefore the use of clonidine is not recommended in paediatric subjects under 18 years.
    Patients with renal impairment: Clonnirit should be used with caution in patients with renal insufficiency. Careful monitoring of blood pressure is required.


    Prophylaxis of migraine and recurrent vascular headache, but not acute attacks. Treatment of menopausal flushing.


    Clonnirit should not be used in patients with severe bradyarrhythmia resulting from either sick-sinus syndrome or AV block of 2nd or 3rd degree, or in patients with known hypersensitivity to the active ingredient, clonidine, or other components of the product.
    In case of rare hereditary conditions that may be incompatible with an excipient of the product the use of the product is contraindicated.

    Rafa Laboratories Ltd.